<DOC>
	<DOCNO>NCT00904176</DOCNO>
	<brief_summary>The purpose study determine Dapagliflozin effect pharmacokinetics ( PK ) pharmacodynamics ( PD ) warfarin dapagliflozin coadministered warfarin . Also , Dapagliflozin effect PK digoxin dapagliflozin coadministered digoxin .</brief_summary>
	<brief_title>Study Effect Dapagliflozin Pharmacokinetics Warfarin Digoxin Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Healthy subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Body Mass Index ( BMI ) 18 32 kg/m² , inclusive . BMI = weight ( kg ) / [ height ( ) ] ² Women childbearing potential ( ie , postmenopausal surgically sterile ) men , age 18 45 WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal Any significant acute chronic medical illness relevant trauma ( e.g . history chronic hypertension , bacterial endocarditis , hemorrhagic stroke , motor vehicle accident result significant head trauma internal injury ) History important arrhythmia determine Investigator , include limited ventricular fibrillation , ventricular tachycardia , AV block , WolffParkinsonWhite Syndrome , sinus bradycardia ( define study heart rate &lt; 50 bpm base vital sign ECG perform within 21 day Study Day 1 ) History evidence abnormal bleed coagulation disorder ( e.g. , history prolong bleed dental procedure , pregnancy delivery , previous surgery injury ) and/or first degree relative 50 year age history abnormal bleeding coagulation disorder per patient 's report History unexplained syncope Presence external hemorrhoid sign rectal bleed physical exam Positive fecal occult blood ( FOB ) , use Hemoccult Sensa® assay ( equivalent ) , hematuria ( trace ) , unless deem clinically significant Investigator Medical Monitor screen dose Platelet count &lt; 150,000 cells/µL screen dose INR aPTT value upper limit normal ( ULN ) screen dose Hemoglobin hematocrit &lt; LLN screen dose Abnormal urinalysis screen dosing ( repeat urinalysis may allow positive hematuria woman ) Glucosuria screen dose Abnormal liver function test ( ALT , AST total bilirubin &gt; 10 % ULN ) screen dose History diabetes mellitus History heart failure History renal insufficiency History recurrent ( defined 3 occurrence per year ) recent vulvovaginal mycotic infection Positive urine screen drug abuse either screen dose Positive blood screen hepatitis C antibody , hepatitis B surface antigen , HIV1 , 2 antibody Protein C Protein S deficiency History allergy SGLT2 inhibitor related compound History allergy warfarin related compound History allergy digoxin related compound Prior exposure dapagliflozin within 3 month Day 1 Exposure investigational drug placebo within 4 week Day 1 Use prescription drug within overthecounter acid controller vitamin K contain product within 4 week prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>